News and Press Releases

ViroCell Biologics signs Master Services Agreement with prominent NCI-designated cancer centre

MSA enables collaboration on full suite of ViroCell’s viral vector manufacturing services to accelerate the cancer centre’s clinical development of novel gene-modified cell therapies Agreement follows ViroCell’s successful GMP manufacture...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 22, 2024

Avallano releases ProtocolCopilot: Powering Clinical Research with AI-driven Protocol Assistance

16 July 2024 -- South Carolina, US -- Avallano is launching ProtocolCopilot, an innovative AI-driven clinical research protocol assistant designed to transform the way biopharmaceutical companies and clinical research sites...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: July 16, 2024

Greenville, South Carolina, 29609

Signant Health Appoints 20-Year Life Sciences Veteran Paul Richmond to executive leadership team as chief commercial officer

15 July 2024 – Pennsylvania, US – Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Paul Richmond as chief commercial officer. A...

Category: Clinical Trials, Other, Pharmaceutical
Posted: July 16, 2024

4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462

Clinical Trial Media Has Increased Patient Randomisations Up to 50% Among Participants Enrolled Through Its Human-Tech Recruiting Approach

With 50 new on-staff nurses and its machine learning-powered pre-screening technology driving a 15% increase in qualified clinical trial candidates, the trial recruitment company is complementing tech efficiencies with personalised...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 11, 2024

100 Motor Parkway, Suite 528 Hauppauge, NY 11788

Pan Cancer T secures €4.25m in Seed Extension Round to advance next-generation T cell therapies

July 11 2024, Rotterdam, the Netherlands – Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25m Seed...

Category: Drug Delivery
Posted: July 11, 2024

Marconistraat 16 3029 AK, Rotterdam The Netherlands

Concr launches trial using digital twins for outcome prediction in breast cancer

10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...

Category: Biotechnology
Posted: July 10, 2024

11 Milbrook, Esher, KT10 9EJ, UK

Pascal Piedbois MD PhD joins One2Treat as chief medical officer to advance patient-centric innovation in clinical trial design and market access

One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments.  9 July 2024 -- Brussels, Belgium -- In this...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: July 10, 2024

Rue Emile Francqui, 1-1435 Mont-Saint-Guibert, Belgium

Epsilogen announces CTA approval for phase 1b trial of MOv18 IgE in platinum-resistant ovarian cancer

Phase 1b study expected to initiate in H2 2024 Previously reported phase 1 results showed MOv18 IgE to be safe and well-tolerated, with evidence of anti-tumour activity. 8 July 2024...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 8, 2024

Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH

Spur provides update on FLT201 and planned phase III clinical trial

8 July 2024 -- London, UK -- Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, notes that its portfolio company...

Category: Clinical Trials, Other, Pharmaceutical
Posted: July 8, 2024

2nd Floor, 8 Bloomsbury Street, London, WC1B 3SR

Stockholm 3 commercially available in the US

A3P Biomedical AB, a leading Swedish diagnostics company specializing in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, are excited to announce that Stockholm3 for early detection...

Category: Biotechnology
Posted: July 3, 2024

Kungsgatan 24, SE 111 35 Stockholm, Sweden

Phase 2b Influenza Field Study Contract

hVIVO to enrol up to 1,000 healthy volunteers as part of a multicentre field study testing an influenza drug candidate, with hVIVO selected as the sole UK clinical site Largest...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024

40 Bank Street, Floor 24, London, E14 5NR

1nhaler hires pharma industry leaders for key roles ahead of clinical trials

Edinburgh-based 1nhaler has appointed two experts in inhalation and respiratory medicines to the board as it looks to accelerate the development and market-readiness of its novel single use inhaler device....

Category: Clinical Trials, Other
Posted: July 1, 2024

1 (2F3) Jessfield Terrace, Edinburgh, Scotland, EH6 4JR

RYBREVANT (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations

Approval is supported by the phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60% compared to chemotherapy alone 28...

Category: Clinical Trials, Pharmaceutical
Posted: June 28, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

CHMP adopts positive opinion for BALVERSA (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations

Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers The CHMP’s recommendation is based on results...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 28, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

New study investigates link between toxic element exposure and Alzheimer’s disease risk

25 June 2024 -- Malvern, UK -- A comprehensive study is currently underway to clarify the relationship between Alzheimer's disease and related dementias (AD/ADRD) and four toxic elements: lead, mercury, arsenic...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 27, 2024

Enigma Business Park Grovewood Road Malvern WR14 1XZ United Kingdom